CaseBioscience Collaborates on $7.3 Million ARPA-H Project for Cell Therapy Preservation

CaseBioscience Joins Forces to Revolutionize Cell Therapy Preservation

In an exciting development for the biomedical field, CaseBioscience® has recently announced its involvement in a groundbreaking project led by Likarda, which has secured up to $7.3 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This initiative is part of the BioStabilization Systems (BoSS) program designed to innovate the way living cells are stored and transported, focusing on developing technologies that can maintain cellular integrity at room temperature, thereby eliminating the need for refrigeration. The end goal? To make advanced biological medicines as accessible as over-the-counter medications, such as aspirin.

The team behind this initiative, known as the Reversible Ambient Biostabilization (RAB) team, is among just three selected for the BoSS program. Bringing together a diverse array of expertise—including preservation science, cell biology, bioengineering, and immunology—the collaboration aims to pave new paths for the storage and transport of living cellular medicines. This effort seeks to minimize reliance on cold-chain logistics, which has historically complicated the distribution of critical therapies.

Dr. Kevin Flynn, Chief Scientific Officer at CaseBioscience, expressed his enthusiasm about this collaboration, stating, "We are thrilled to be part of a program that combines extraordinary scientific expertise and resources. The potential to significantly advance our field is immense, and we are eager to explore new territories in biopreservation."

Previously, many cell therapies have been hindered by the challenges associated with maintaining their viability during transportation. Typically requiring controlled environments for storage, these therapies present a logistical nightmare that restricts patient access. However, through innovative approaches that integrate novel bioengineering and cell-protective techniques, the RAB team aims to transform this landscape, ultimately making these critical treatments far more accessible.

The project commences with an initial 15-month phase, having kicked off on September 24, 2026. Collaboration will be key, as the team will work closely with institutions such as the University of Colorado Boulder and companies like Fresenius Kabi and MiNK Therapeutics to share knowledge and foster progress.

Emphasizing the importance of these developments, Dr. John Baust—an authority in biopreservation and a collaborator on the project—highlighted the historical challenges in stabilizing living cells in a dry state, stating, "Though efforts to preserve living cells at ambient temperatures have spanned more than two decades, the journey has been fraught with scientific and engineering challenges. The chance to tackle these issues from multiple scientific avenues simultaneously, thanks to ARPA-H's support, is unique. If we succeed, this could dramatically change the paradigm regarding how biopreserving is approached."

The potential impact of this research is profound, especially for patients requiring cell-based products, which have shown promise in treating various serious health conditions, including cancer. By overcoming existing logistical barriers, this initiative could broaden access to essential therapies, allowing more individuals to benefit from cutting-edge medical advancements.

Ultimately, the involvement of CaseBioscience in this project exemplifies its commitment to driving innovation within the life sciences sector. With established expertise in clinical media formulation and cellular metabolism, CaseBioscience is uniquely positioned to contribute to and shape the future of biopreservation in cell therapy and regenerative medicine.

This initiative not only marks a significant step forward in the field of biomedical research but also underscores the vital role of collaboration among various stakeholders to revolutionize healthcare solutions. As the team embarks on this promising venture, the path toward more accessible and efficient cell therapies is beginning to take shape, potentially leading to revolutionary changes in patient care and treatment methodologies.